Colossal Biosciences seeks funding at up to $30B valuation, tripling prior worth
De-extinction startup Colossal Biosciences is reportedly in talks to raise a new round of capital. The company is targeting a valuation between $20 billion and $30 billion. If achieved, this would represent roughly double to triple its previous valuation. The fundraising discussions signal growing investor interest in the biotech firm's work on reviving extinct species.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.


Discussion (0)
Log in to join the discussion and vote.
Log in